Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fresenius Medical Care AG & Co. KGaA (FMS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
18.97+0.32 (+1.72%)
At close: 04:00PM EDT
19.30 +0.33 (+1.74%)
After hours: 07:09PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close18.65
Open18.95
Bid18.73 x 1300
Ask19.23 x 1100
Day's Range18.84 - 19.06
52 Week Range18.16 - 40.85
Volume690,410
Avg. Volume809,203
Market Cap11.231B
Beta (5Y Monthly)0.90
PE Ratio (TTM)13.55
EPS (TTM)1.40
Earnings DateN/A
Forward Dividend & Yield0.71 (3.80%)
Ex-Dividend DateMay 13, 2022
1y Target Est27.94
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
19% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for FMS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fresenius Medical Care AG
    Analyst Report: Fresenius Medical Care AG & Co. KGaAFresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of September 2021. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
    Rating
    Fair Value
    Economic Moat
    20 days agoMorningstar
View more
  • Moody's

    Fresenius Medical Care Holdings, Inc. -- Moody's affirms Fresenius Medical Care Holdings' Baa3 rating; outlook stable

    Rating Action: Moody's affirms Fresenius Medical Care Holdings' Baa3 rating; outlook stableGlobal Credit Research - 15 Aug 2022Frankfurt am Main, August 15, 2022 -- Moody's Investors Service ("Moody's") has today affirmed Fresenius Medical Care Holdings, Inc.'s (FMCH or the company) Baa3 long-term issuer rating. The outlook remains stable.RATINGS RATIONALEToday's rating action reflects the company's standalone credit profile, as well as the fact that FMCH is a significant subsidiary of Fresenius Medical Care AG & Co. KGaA (FMC, Baa3 stable) because this entity owns and consolidates all the US operating subsidiaries of the parent. FMCH contributed around 70% of the parent company's revenue and around 76% of its Moody's adjusted EBITDA in 2021.FMCH's standalone operating profitability and credit metrics are relatively similar to those of FMC, and they are not likely to change significantly over time.

  • Moody's

    Fresenius Finance Ireland II Plc -- Moody's affirms Fresenius SE's Baa3 rating; outlook stable

    Rating Action: Moody's affirms Fresenius SE's Baa3 rating; outlook stableGlobal Credit Research - 15 Aug 2022Frankfurt am Main, August 15, 2022 -- Moody's Investors Service ("Moody's") has today affirmed Fresenius SE & Co. KGaA's (FSE or the company) Baa3 long-term issuer rating. During the period of subdued operating performance, which will likely last until end of 2023, Moody's expects FSE will remain fully committed to its investment grade rating by prioritizing its public commitment to the 3-3.5x net leverage range over capital allocation to M&A and shareholders' distribution. The rating as of today is weakly positioned.

  • Moody's

    Fresenius Medical Care US Finance III, Inc. -- Moody's affirms Fresenius Medical Care's Baa3 rating; outlook stable

    Rating Action: Moody's affirms Fresenius Medical Care's Baa3 rating; outlook stableGlobal Credit Research - 15 Aug 2022Frankfurt am Main, August 15, 2022 -- Moody's Investors Service ("Moody's") has today affirmed Fresenius Medical Care AG & Co. KGaA's (FMC or the company) Baa3 long-term issuer rating. The outlook remains stable.A full list of affected ratings can be found at the end of this press release.RATINGS RATIONALEToday's rating affirmation with stable outlook reflects Moody's expectations that current operating headwinds are mostly temporary. During this period of subdued operating performance, which will likely last until end of 2023, Moody's expects FMC will remain fully committed to its investment grade rating by prioritizing its public commitment to the 3-3.5x net leverage range over capital allocation to M&A and shareholders' distribution.

Advertisement
Advertisement